PRP/OSI sustained-release Macugen collaboration
Executive Summary
A PR Pharmaceuticals/OSI collaboration to develop sustained-release Macugen, announced Jan. 11, grants OSI rights to license PRP's ProPhase encapsulation technology. Under the agreement, PRP will develop the new formulations of the neovascular age-related macular degeneration therapy and test article for non-clinical and clinical trials, while OSI will manage clinical development, manufacturing and marketing. PRP will receive an undisclosed up-front payment from OSI, which recently acquired Macugen (pegaptanib) developer Eyetech, as well as future milestone payments and royalties on net sales of any product resulting from the collaboration. Macugen is expected to face competition in the AMD market from Genentech's Lucentis in early 2006 (1"The Pink Sheet" Nov. 28, 2005, p. 4)...
You may also be interested in...
OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.